- ETST is focused on its developing role as an international leader in the CBD space
- The company recently filed a securities registration statement with the SEC
- ETST recently named a pharmaceutical and orthopedic expert as head of its new sales division
Earth Science Tech Inc. (OTCQB: ETST) is an innovative science-based biotechnology company operating in the fields of hemp-derived cannabinoids, nutraceuticals, pharmaceuticals, medical devices and research and development (R&D). The company, based in Doral, Florida, recently announced its establishment of a new sales division specifically focusing on CBD products of therapeutic and pharmaceutical grades.
The company’s CBD (cannabidiol) oil is 100 percent natural and organic. In contrast to its competitors, which may use dangerous hemp extraction methods including toxic solvents or high heat, ETST’s CBD-rich hemp does not contain any synthetic cannabinoids and is not an isolate. Through its subsidiaries, Earth Science Tech is focused on developing its role as a world leader in the CBD space.
The impetus behind this new division comes from increased interest in CBD products across multiple medical communities, including medical, holistic and alternative medicine (http://ibn.fm/ugOM9). The division will be headed by Erika Franck, who has been serving as the company’s clinical and therapeutics sales director for several weeks. In her new role, Franck will be working with medical providers, chiropractors, acupuncturists, holistic wellness practitioners and veterinarians, utilizing her years of experience in the medical field to bring the benefits of CBD to a myriad of industries.
Franck’s expertise includes CNS (central nervous system), psychiatry, cardiology, pulmonology, asthmas, allergy and dermatology, which she cultivated through working in the pharmaceuticals and orthopedics industry for over 15 years. During her time in pharmaceuticals, Franck launched two new drugs into the medical market: Lexapro (a type of antidepressant) and Benicar (a drug used to treat high blood pressure).
“I am thrilled to be part of this amazing team and to have the opportunity to apply my expertise in spearheading this new clinical division for ETST,” Franck said in a news release. “Our shared vision is to improve patients’ quality of life, and I am honored to participate in ETST’s growth as we achieve this mission.”
ETST president, director, and chairman Nickolas Tabraue announced his excitement at adding Franck’s leadership experience to the division. “She brings a wealth of knowledge and experience to the team that will be invaluable as we pursue opportunities through this exciting new sales channel,” Tabraue added. “We pride ourselves on hiring the very best and brightest, and Erika certainly fits that criteria.”
Recently, ETST filed its Form S-1/A securities registration statement (http://ibn.fm/7ebl1). It was filed with the U.S. Securities and Exchange Commission (SEC) on September 10, 2019. The document details the company’s long-term strategy, partnerships and strategic focus, as well as providing an overview of its subsidiaries.
The company continues to expand its work in the pharmaceutical and medical device sectors through its subsidiaries, which include Nutrition Empire Inc., Earth Science Pharmaceutical Inc., Cannabis Therapeutics Inc. (CTI), and KannaBidioiD (KBD). ETST also has its Canadian subsidiary, Canna Inno Laboratories Inc.
ETST continues to focus on the CBD market with its broad array of well-branded products and premier distribution. For investors, the company has a strong in-house team and strategic partnerships to foster continued growth. ETST is advancing further projects using its high-grade and inventive products.
For more information, visit the company’s website at www.EarthScienceTech.com
NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
